הסקירה באדיבות מדיקונטקסט: Last Updated: 2001-07-31 13:37:05 EDT (Reuters Health)
WESTPORT, CT (Reuters Health) – The leukotriene receptor antagonist pranlukast appears protective against aspirin-induced bronchoconstriction in sensitive asthmatics, according to Japanese researchers.
Dr. Terufumi Shimoda and colleagues, from Nagasaki University School of Medicine, studied the effect of oral provocation with aspirin in a group of seven aspirin-sensitive asthmatics and seven aspirin-tolerant asthmatics.
The researchers report, in the July issue of the Annals of Allergy Asthma and Immunology, that the subjects underwent bronchial provocation and other testing. These procedures were conducted both with and without administration of a single oral dose of pranlukast 2 hours before aspirin challenge.
In the sensitive asthmatics, challenge without pretreatment prompted an asthma attack and caused an immediate increase in sputum concentration of leukotrienes and eosinophil cationic protein (ECP) and urine concentrations of leukotriene E4. No such reactions were seen in the tolerant group.
Pranlukast pretreatment led to a reduction in bronchoconstriction in the aspirin-sensitive group and stopped the increase in sputum ECP but did not affect sputum leukotrienes and urinary leukotriene E4.
In light of these findings, the researchers conclude that pranlukast is effective in such patients "probably" because of "an inhibition of mechanisms involved in airway inflammation."
Ann Allergy Asthma Immunol 2001;87:74-79.
e-Med Tools
קצר קולע וממוקד
e-Med סמינרים
אי-מד תחקירים
Medscape Tools
Journal Club
מרכזי מידע ושירות
Facebook
מידע למפרסם
מאגר תרופות
מאגר אנשי המקצוע
אינדקס שימושי
חדשות משה"ב
eMed HealthClub
מחקרים קליניים
השאירו תגובה
רוצה להצטרף לדיון?תרגישו חופשי לתרום!